BioMarin Pharmaceutical

BioMarin Pharmaceutical BMRN Stock

$63.13   2.769859%
Add to favorites
Market Cap
$12.23B
LOW - HIGH [24H]
$61.00 - $64.00
VOLUME [24H]
$2.21M
P/E Ratio
0
Earnings per share
-$0.10
ISIN
US09061G1013
Price   Prediction

BioMarin Pharmaceutical Price Chart

Sorry, that's all we've gotfor now...

BioMarin Pharmaceutical (BMRN) stock price today is 63.13 USD on Tech Market Large (+2.77% on the day). Updated .

BioMarin Pharmaceutical BMRN Financial and Trading Overview

BioMarin Pharmaceutical stock price 63.13 USD
Previous Close 57.99 USD
Open 57.95 USD
Bid 55.05 USD x 100
Ask 60.67 USD x 100
Day's Range 57.33 - 58.65 USD
52 Week Range 49.26 - 70.98 USD
Volume 2.25M USD
Avg. Volume 2.2M USD
Market Cap 11.33B USD
Beta (5Y Monthly) 0.226
PE Ratio (TTM) N/A
EPS (TTM) -0.1 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 90.19 USD

BMRN Valuation Measures

Enterprise Value 14.79B USD
Trailing P/E N/A
Forward P/E 9.250827
PEG Ratio (5 yr expected) 0.53
Price/Sales (ttm) 3.1005979
Price/Book (mrq) 1.8113991
Enterprise Value/Revenue 4.046
Enterprise Value/EBITDA 17.295

Trading Information

BioMarin Pharmaceutical Stock Price History

Beta (5Y Monthly) 0.226
52-Week Change 11.32%
S&P500 52-Week Change 10.51%
52 Week High 70.98 USD
52 Week Low 49.26 USD
50-Day Moving Average 58.56 USD
200-Day Moving Average 58.47 USD

BMRN Share Statistics

Avg. Volume (3 month) 2.2M USD
Avg. Daily Volume (10-Days) 2.1M USD
Shares Outstanding 193.69M
Float 192.75M
Short Ratio 5.73
% Held by Insiders 0.37%
% Held by Institutions 103.10%
Shares Short 14.12M
Short % of Float 7.30%
Short % of Shares Outstanding 7.29%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin -0.52%
Operating Margin (ttm) 16.34%
Gross Margin 53.21%
EBITDA Margin 23.39%

Management Effectiveness

Return on Assets (ttm) 3.89%
Return on Equity (ttm) -0.30%

Income Statement

Revenue (ttm) 3.66B USD
Revenue Per Share (ttm) 18.95 USD
Quarterly Revenue Growth (yoy) 32.00%
Gross Profit (ttm) 1.94B USD
EBITDA 854.99M USD
Net Income Avi to Common (ttm) -19115000 USD
Diluted EPS (ttm) -0.1
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 736.01M USD
Total Cash Per Share (mrq) 3.8 USD
Total Debt (mrq) 4.19B USD
Total Debt/Equity (mrq) 66.98 USD
Current Ratio (mrq) 2.443
Book Value Per Share (mrq) 32.301

Cash Flow Statement

Operating Cash Flow (ttm) 676.62M USD
Levered Free Cash Flow (ttm) -16042000 USD

Profile of BioMarin Pharmaceutical

Country United States
State CA
City San Rafael
Address 770 Lindaro Street
ZIP 94901
Phone 415 506 6700
Website https://www.biomarin.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 3221

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Q&A For BioMarin Pharmaceutical Stock

What is a current BMRN stock price?

BioMarin Pharmaceutical BMRN stock price today per share is 63.13 USD.

How to purchase BioMarin Pharmaceutical stock?

You can buy BMRN shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for BioMarin Pharmaceutical?

The stock symbol or ticker of BioMarin Pharmaceutical is BMRN.

Which industry does the BioMarin Pharmaceutical company belong to?

The BioMarin Pharmaceutical industry is Biotechnology.

How many shares does BioMarin Pharmaceutical have in circulation?

The max supply of BioMarin Pharmaceutical shares is 193.69M.

What is BioMarin Pharmaceutical Price to Earnings Ratio (PE Ratio)?

BioMarin Pharmaceutical PE Ratio is now.

What was BioMarin Pharmaceutical earnings per share over the trailing 12 months (TTM)?

BioMarin Pharmaceutical EPS is -0.1 USD over the trailing 12 months.

Which sector does the BioMarin Pharmaceutical company belong to?

The BioMarin Pharmaceutical sector is Healthcare.

BioMarin Pharmaceutical BMRN included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24201.34 USD —
-0.94
4.68B USD — 24005.47 USD — 24939.62 USD — — 4.68B USD —
us Dow Jones U.S. Biotechnology In DJUSBT US 3888.92 USD —
-0.27
51.92M USD — 3856.79 USD — 3919.64 USD — — 51.92M USD —
us US Tech DM Ex Japan Large Mid Ca NQDMXJPLMAUD US 2100.38 AUD 1467.26 USD
<0.01
— — 2100.38 AUD 1467.26 USD 2100.38 AUD 1467.26 USD — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech Biotechnology Total Retu XNBI US 7603.91 USD —
-0.19
— — 7546.09 USD — 7685.86 USD — — — —
us US Tech Q-50 NXTQ US 1179.02 USD —
-0.05
— — 1168.83 USD — 1196.31 USD — — — —
us US Tech Global Select Market Com NQGS US 11949.46 USD —
-0.71
— — 11825.17 USD — 12288.24 USD — — — —
us US Tech Next Generation 100 Inde NGX US 1686.49 USD —
-0.59
— — 1673.01 USD — 1717.15 USD — — — —
us US Tech Biotechnology NBI US 6965.89 USD —
-0.08
— — 6905.76 USD — 7033.67 USD — — — —
us US Tech Health Care IXHC US 1317.49 USD —
-0.52
— — 1309.03 USD — 1333.62 USD — — — —
us US Tech Composite Total Return XCMP US 29950.1 USD —
-0.8
— — 29671.6 USD — 30826.03 USD — — — —
us US Tech US Smart Pharmaceuticals NQSSPH US 2246.21 USD —
-1.59
— — 2233.15 USD — 2284.66 USD — — — —
$2.17T
Total marketcap
$71.79B
Total volume
BTC 58.07%   •   ETH 9.95%
Dominance
Select currency